Skin cancer evaluation in transplant patients: A physician opinion survey with recommendations

Clinical Transplantation

Volumn 29, Issue 2, 2015, Pages 110-117

  Lloyd, Amanda ^a   Klintmalm, Goran ^a   Qin, Huanying ^a   Menter, Alan ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Basal cell carcinoma; Immunosuppression; Non melanoma skin cancer; Screening; Squamous cell carcinoma; Transplant

Indexed keywords

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER STAGING; CLINICAL ARTICLE; DERMATOLOGIST; FEMALE; GRAFT RECIPIENT; HEALTH CARE SURVEY; HUMAN; MALE; MEDICAL DECISION MAKING; MIDDLE AGED; PATIENT REFERRAL; PHYSICIAN; PRIORITY JOURNAL; SKIN CANCER; CARCINOMA, SQUAMOUS CELL; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SKIN NEOPLASMS; TRANSPLANTATION; UNITED STATES;

CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TRANSPLANTS; UNITED STATES;

EID: 84921509364     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12490     Document Type: Article

References (76)

1. Dantal J. De novo post-transplantation malignancies: incidence and risk factors. Cancer Treat Res 2009: 146: 11.
2. Smith KJ, Hamza S, Skelton H. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients. Dermatol Surg 2004: 30: 634.
3. O'Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: Part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011: 65: 263.
4. O'Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: Part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011: 65: 253.
5. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003: 348: 1681.
6. Sheil AG, Disney AP, Mathew TH, Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993: 25: 1383.
7. Martinez J, Otley CC, Stasko T et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003: 139: 301.
8. Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999: 40: 27.
9. Lindelof B, Jarnvik J, Ternesten-Bratel A, Granath F, Hedblad MA. Mortality and clinicopathological features of cutaneous squamous cell carcinoma in organ transplant recipients: a study of the Swedish cohort. Acta Derm Venereol 2006: 86: 219.
10. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000: 143: 513.
11. O'Reilly F, Traywick C, Pennie ML, Foster JK, Chen SC. Baseline quality of life and anxiety in solid organ transplant recipients: a pilot study. Dermatol Surg 2006: 32: 1480.
12. Moloney FJ, Keane S, O'Kelly P, Conlon PJ, Murphy GM. The impact of skin disease following renal transplantation on quality of life. Br J Dermatol 2005: 153: 574.
13. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991: 23: 1101.
14. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients-where do we stand today? Am J Transplant 2008: 8: 2192.
15. Cooper JZ, Brown MD. Special concern about squamous cell carcinoma of the scalp in organ transplant recipients. Arch Dermatol 2006: 142: 755.
16. Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000: 11: S1.
17. Otley CC, Berg D, Ulrich C et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 2006: 154: 395.
18. Otley CC. Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer. Dermatol Surg 2000: 26: 709.
19. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002: 47: 1; quiz 8-20.
20. Stasko T, Brown MD, Carucci JA et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004: 30: 642.
21. Herman S, Rogers HD, Ratner D. Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients. Skinmed 2007: 6: 234.
22. Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987: 44: 429.
23. O'Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005: 309: 1871.
24. Norman KG, Canter JA, Shi M, Milne GL, Morrow JD, Sligh JE. Cyclosporine A suppresses keratinocyte cell death through MPTP inhibition in a model for skin cancer in organ transplant recipients. Mitochondrion 2010: 10: 94.
25. Christenson LJ, Geusau A, Ferrandiz C et al. Specialty clinics for the dermatologic care of solid-organ transplant recipients. Dermatol Surg 2004: 30: 598.
26. Otley CC, Griffin MD, Charlton MR, Edwards BS, Neuburg M, Stasko T. Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks. Br J Dermatol 2007: 157: 1183.
27. Clowers-Webb HE, Christenson LJ, Phillips PK et al. Educational outcomes regarding skin cancer in organ transplant recipients: randomized intervention of intensive vs standard education. Arch Dermatol 2006: 142: 712.
28. Ismail F, Mitchell L, Casabonne D et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol 2006: 155: 916.
29. Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 2005: 141: 456.
30. Traywick C, O'Reilly FM. Management of skin cancer in solid organ transplant recipients. Dermatol Ther 2005: 18: 12.
31. Greenberg JN, Zwald FO. Management of skin cancer in solid-organ transplant recipients: a multidisciplinary approach. Dermatol Clin 2011: 29: 231.
32. Mahe E, Morelon E, Fermanian J et al. Renal-transplant recipients and sun protection. Transplantation 2004: 78: 741.
33. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000: 23: 101.
34. Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999: 40: 177.
35. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990: 49: 506.
36. Adamson R, Obispo E, Dychter S et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study. Transplant Proc 1998: 30: 1124.
37. Veness MJ, Quinn DI, Ong CS et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999: 85: 1758.
38. Bangash HK, Colegio OR. Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients. Curr Treat Options Oncol 2012: 13: 354.
39. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010: 10: 1889.
40. Colegio OR, Billingsley EM. Skin cancer in transplant recipients, out of the woods. Scientific retreat of the ITSCC and SCOPE. Am J Transplant 2011: 11: 1584.
41. Otley CC, Maragh SLH. Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy. Dermatol Surg 2005: 31: 163.
42. Hofbauer GF, Attard NR, Harwood CA et al. Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine. Am J Transplant 2012: 12: 218.
43. O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006: 25: 1186.
44. Braconnier P, Del Marmol V, Broeders N et al. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study. Nephrol Dial Transplant 2012: 27: 2547.
45. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013: 31: 1317.
46. Carroll RP, Hester J, Wood KJ, Harden PN. Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype. Nephrol Dial Transplant 2013: 28: 462.
47. Salgo R, Gossmann J, Schofer H et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010: 10: 1385.
48. Alberu J, Pascoe MD, Campistol JM et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011: 92: 303.
49. Mungamuri SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006: 66: 4715.
50. Euvrard S, Morelon E, Rostaing L et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012: 367: 329.
51. Wu X, Nguyen B-C, Dziunycz P et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010: 465: 368.
52. Leisenring W, Friedman DL, Flowers MED, Schwartz JL, Deeg HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006: 24: 1119.
53. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997: 336: 897.
54. Rizzo JD, Curtis RE, Socie G et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009: 113: 1175.
55. Wolff D, Schleuning M, von Harsdorf S et al. Consensus Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011: 17: 1.
56. Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976: 38: 683.
57. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002: 73: 665.
58. Couriel D, Saliba R, Hicks K et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004: 104: 649.
59. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013: 72: 517.
60. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011: 20: 119.
61. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005: 32: 2130.
62. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012: 143: 390.
63. Wolverton SE. Comprehensive Dermatologic Drug Therapy. Philadelphia: Saunders, 2001, xix, 954 p.
64. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998: 90: 1278.
65. Richard MA, Barnetche T, Horreau C et al. Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol 2013: 27: 2.
66. Ritchie SA, Patel MJ, Miller SJ. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. Dermatol Surg 2012: 38: 1604.
67. Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005: 141: 985.
68. Ulrich C, Busch JO, Meyer T et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 2006: 155: 451.
69. Euvrard S, Kanitakis J, Thivolet J, Claudy A. Retinoids for the management of dermatological complications of organ transplantation. BioDrugs 1997: 8: 176.
70. Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007: 156: 320.
71. Piaserico S, Belloni Fortina A, Rigotti P et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007: 39: 1847.
72. Bavinck JN, Tieben LM, Van der Woude FJ et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995: 13: 1933.
73. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999: 140: 656.
74. George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002: 43: 269.
75. Ulrich C, Jürgensen JS, Degen A et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009: 161: 78.
76. Cowen EW, Billingsley EM. Awareness of skin cancer by kidney transplant patients. J Am Acad Dermatol 1999: 40: 697.